ArticlePPAR research2008
PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- The Role of CYP3A in Health and Disease.Biomedicines · 2022Review
- Reference Module-Based Analysis of Ovarian Cancer Transcriptome Identifies Important Modules and Potential Drugs.Biochemical genetics · 2022Article
- Enhanced monoacylglycerol lipolysis by ABHD6 promotes NSCLC pathogenesis.EBioMedicine · 2020Article
- Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer.Frontiers in pharmacology · 2020Review
- The Emerging Role of PPAR Beta/Delta in Tumor Angiogenesis.PPAR research · 2020Review
- Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity, to curtail dependence on host tissue: molecular mode.Cancer biology & medicine · 2017Article
- Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.World journal of gastrointestinal pharmacology and therapeutics · 2015Article
- Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death.Carcinogenesis · 2015Review
- Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity.Chemistry & biology · 2014Article
- A comparison of peroxisome proliferator-activated receptor-α agonist and antagonist on human umbilical vein endothelial cells angiogenesis.Advanced biomedical research · 2013Article
- The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer.PPAR research · 2012Article
- Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats.International journal of peptides · 2012Article
- Cyclooxygenases and lipoxygenases in cancer.Cancer metastasis reviews · 2011Review
- EET signaling in cancer.Cancer metastasis reviews · 2011Review
- The anti-tumorigenic properties of peroxisomal proliferator-activated receptor alpha are arachidonic acid epoxygenase-mediated.The Journal of biological chemistry · 2010Article
- Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products.Wiley interdisciplinary reviews. Systems biology and medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor family of ligand-activated transcription factors. This subfamily is composed of three members-PPARalpha, PPARdelta, and PPARgamma-that differ in their cell and tissue distribution as well as in their target genes. PPARalpha is abundantly expressed in liver, brown adipose tissue, kidney, intestine, heart, and skeletal muscle; and its ligands have been used to treat diseases such as obesity and diabetes. The recent finding that members of the PPAR family, including the PPARalpha, are expressed by tumor and endothelial cells together with the observation that PPAR ligands regulate cell growth, survival, migration, and invasion, suggested that PPARs also play a role in cancer. In this review, we focus on the contribution of PPARalpha to tumor and endothelial cell functions and provide compelling evidence that PPARalpha can be viewed as a new class of ligand activated tumor "suppressor" gene with antiangiogenic and antitumorigenic activities. Given that PPAR ligands are currently used in medicine as hypolipidemic drugs with excellent tolerance and limited toxicity, PPARalpha activation might offer a novel and potentially low-toxic approach for the treatment of tumor-associated angiogenesis and cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.